Natural course of treated and untreated chronic HCV infection: Results of the nationwide Hepnet.Greece cohort study

Alimentary Pharmacology and Therapeutics

Volumn 29, Issue 10, 2009, Pages 1121-1130

  Manesis, E K ^a   Papatheodoridis, G V ^b   Touloumi, G ^c   Karafoulidou, A ^d   Ketikoglou, J ^b   Kitis, G E ^e   Antoniou, A ^c   Kanatakis, S ^f   Koutsounas, S J ^g   Vafiadis, I ^c  

^a Liver Unit   (Greece)

^b HIPPOKRATION HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d LAIKO GENERAL HOSPITAL   (Greece)

^e G Papanikolaou Hospital   (Greece)

^f RED CROSS HOSPITAL   (Greece)

^g Hepatology Service   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON ALPHA; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DRUG EFFECT; FEMALE; FOLLOW UP; GREECE; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER PROTECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; AGED; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDEMIOLOGIC METHODS; FEMALE; GREECE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 64849107049     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.03974.x     Document Type: Article

References (41)

1. WHO. Hepatitis C. Fact Sheet no. 164. Geneva : WHO, 2000.
2. Sypsa V, Touloumi G, Tassopoulos NC, et al. Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection. J Viral Hep 2004 11 : 366 74.
3. Papadimitropoulos V, Gioustozi A, Papaioannou C, et al. Prevalence of HCV infection in the general population of various regions of Greece. In : Hadziyannis S, ed. Hepatitis C Technorama Editions, Athens Greece, 1998 : 163 70.
4. Wiese M, Grungreiff K, Guthoff W, Lafrenz M, Oesen U, Porst H. East German Hepatitis C Study Group. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany - a 25-year multicenter study. J Hepatol 2005 43 : 590 8.
5. Santantonio T, Sinisi E, Guastadisegni A, et al. Natural course of acute hepatitis C: a long-term prospective study. Dig Liver Dis 2003 35 : 104 13.
6. Persico M, Perrotta S, Persico E, et al. Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years. J Viral Hepat 2006 13 : 290 6.
7. Fabris C, Smirne C, Toniutto P, et al. Assessment of liver fibrosis progression in patients with chronic hepatitis C and normal alanine aminotransferase values: The role of AST to the platelet ratio index. Clin Biochem 2006 39 : 339 43.
8. Massard J, Ratziu V, Thabut D, et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006 44 (Suppl S19 24.
9. Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004 53 : 744 9.
10. Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006 43 : 1303 10.
11. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 2007 147 : 677 84.
12. Gramenzi A, Andreone P, Fiorino S, et al. Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut 2001 48 : 843 8.
13. Okanoue T, Minami M, Makiyama A, Sumida Y, Yasui K, Itoh Y. Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy. Clin Gastroenterol Hepatol 2005 10 (Suppl 2 S89 91.
14. Arase Y, Ikeda K, Tsubota A, et al. Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection. Intervirology 2004 47 : 355 61.
15. Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther 2001 15 : 689 98.
16. Cammà C, Di Bona D, Schepis F, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004 39 : 333 42.
17. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002 122 : 1303 13.
18. Trépo C, Marion-Audibert AM, Samuel D, Guyader D, Fontanges T. Maintenance therapy for chronic hepatitis C. Gastroenterol Clin Biol 2007 31 (8-9 Pt 3 4S29 33.
19. Ke-Qin H, Tong M. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999 29 : 1311 6.
20. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007 147 : 677 84.
21. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995 22 : 696 9.
22. Colli A, Fraquelli M, Andreoletti M, Marino B, Zuccoli E, Conte D. Severe liver fibrosis or cirrhosis: accuracy of US for detection - analysis of 300 cases. Radiology 2003 227 : 89 94.
23. Hadziyannis SJ, Sette H Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346 55.
24. Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001 121 : 101 9.
25. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 65.
26. Friend MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 82.
27. Strader DB, Wright T, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004 39 : 1147 71.
28. Abergel A, Hezode C, Leroy V, et al. Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b. J Viral Hepat 2006 13 : 811 20.
29. Di Marco V, Almasio PL, Ferraro D, et al. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 2007 47 : 484 91.
30. Ito Y, Yamamoto N, Nakata R, et al. Delayed development of hepatocellular carcinoma during long-term follow-up after eradication of hepatitis C virus by interferon therapy. World J Gastroenterol 2005 11 : 7218 21.
31. Kojima H, Hongo Y, Harada H, et al. Long-term histological prognosis and serum fibrosis markers in chronic hepatitis C patients treated with interferon. J Gastroenterol Hepatol 2001 16 : 1015 21.
32. Takimoto M, Ohkoshi S, Ichida T, et al. Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients. Dig Dis Sci 2002 47 : 170 6.
33. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low -dose peginterferon. N Engl J Med 2008 359 : 2429 41.
34. Perumalswami P, Kleiner DE, Lutchman G, et al. Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology 2006 43 : 780 7.
35. Minola E, Prati D, Suter F, et al. Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood 2002 99 : 4588 91.
36. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002 5 (Suppl 1 S47 56.
37. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001 34 : 730 9.
38. Hiramatsu N, Oze T, Tsuda N, et al. Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy? Hepatol Res 2006 35 : 185 9.
39. Iwasaki Y, Ikeda H, Araki Y, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006 43 : 54 63.
40. Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006 130 : 225 30.
41. Thabut D, Le Calvez S, Thibault V, et al. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol 2006 101 : 1260 7.